Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 in advanced solid tumors with BRAF V600 mutation
NCT05528406Phase 2Unknown
- Sponsor
- Henlius
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of HLX208 in solid tumor, sponsored by Henlius. Status: unknown.
02
Drugs
HLX208
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05528406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528406.